RxDoctor Payments Data

Clare Holmes

Physician Assistant · Lewes, DENPI 1558966614

Payments from drug & device makers

$1,743in general payments, 2019–2025

Across 48 payments — averaging $36.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$327
  • Mallinckrodt Hospital Products Inc.$280
  • AbbVie$241
  • Viiv Healthcare Company$187
  • Paratek Pharmaceuticals, Inc.$168
  • GSK$114
  • plus $426 from 10 others

What the payments were for

  • Food & beverage$1,69397%
  • Education$503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,743 in reported general payments places this provider in the 85th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$55,834
Medicare patients
210
Services billed
1,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$380,204
ArikayceAmikacin Liposomal/Neb.Accessr14$210,580
OdefseyEmtricitab/Rilpiviri/Tenof Ala34$139,367
GenvoyaElviteg/Cob/Emtri/Tenof Alafen28$109,524
JulucaDolutegravir/Rilpivirine26$94,327
DescovyEmtricitabine/Tenofov Alafenam20$42,475
PrezcobixDarunavir/Cobicistat14$33,273
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl62$4,132
Bicillin L-APenicillin G Benzathine12$3,520
Meropenem16$2,604
Doxycycline Monohydrate46$2,540
Amoxicillin52$1,555
Azithromycin99$1,430
Rifampin11$1,105
Cefadroxil15$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$327$532,204132 claims
Insmed, Inc.Arikayce$32$210,58014 claims
Viiv Healthcare CompanyJuluca$187$94,32726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →